These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 9269701

  • 21. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
    Sato A, Hayashi K, Saruta T.
    Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
    [Abstract] [Full Text] [Related]

  • 22. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S, Aurell M.
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [Abstract] [Full Text] [Related]

  • 23. Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients.
    Vogt L, de Zeeuw D, Woittiez AJ, Navis G.
    Nephrol Dial Transplant; 2009 Apr; 24(4):1182-9. PubMed ID: 19037084
    [Abstract] [Full Text] [Related]

  • 24. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs.
    Robles NR, Romero B, de Vinuesa EG, Sánchez-Casado E, Cubero JJ.
    Ren Fail; 2010 Jan; 32(2):192-7. PubMed ID: 20199181
    [Abstract] [Full Text] [Related]

  • 25. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure.
    Jorde UP, Vittorio TJ, Dimayuga CA, Homma S, Rizkala A, Le Jemtel TH, Katz SD.
    Am J Cardiol; 2004 Dec 15; 94(12):1501-5. PubMed ID: 15589004
    [Abstract] [Full Text] [Related]

  • 26. Renal hemodynamics and renoprotection.
    Loriga G, Vidili G, Ruggenenti P, Faedda R, Sanna M, Satta AE.
    Nephron Clin Pract; 2008 Dec 15; 110(4):c213-9. PubMed ID: 18974652
    [Abstract] [Full Text] [Related]

  • 27. [Antiproteinuric effect of renin-angiotensin system blockade in patients with normal/lower than 115 mmHg systolic blood pressure].
    Gutiérrez E, González E, Morales E, Herrero JC, Manzanera MJ, García JA, Domínguez-Gil B, Hernández E, Praga M.
    Nefrologia; 2004 Dec 15; 24(6):546-52. PubMed ID: 15683026
    [Abstract] [Full Text] [Related]

  • 28. Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats.
    Windt WA, van Dokkum RP, Kluppel CA, Jeronimus-Stratingh CM, Hut F, de Zeeuw D, Henning RH.
    Eur J Pharmacol; 2008 Feb 02; 580(1-2):231-40. PubMed ID: 18036585
    [Abstract] [Full Text] [Related]

  • 29. Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage.
    Lufft V, Kliem V, Hamkens A, Bleck JS, Eisenberger U, Petersen R, Ehlerding G, Maschek H, Pichlmayr R, Brunkhorst R.
    Clin Transplant; 1998 Oct 02; 12(5):409-15. PubMed ID: 9787950
    [Abstract] [Full Text] [Related]

  • 30. Angiotensin-converting enzyme inhibition and the combination of a beta blocker and a diuretic are equally effective in lowering proteinuria in patients with glomerulonephritis.
    Kloke HJ, Wetzels JF, van Hamersvelt HW, Koene RA, Huysmans FT.
    Nephrol Dial Transplant; 1993 Oct 02; 8(9):808-13. PubMed ID: 8255512
    [Abstract] [Full Text] [Related]

  • 31. Dual renin-angiotensin system blockade at optimal doses for proteinuria.
    Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D.
    Kidney Int; 2002 Sep 02; 62(3):1020-5. PubMed ID: 12164886
    [Abstract] [Full Text] [Related]

  • 32. Effect of the angiotensin converting enzyme inhibitor, captopril, on proteinuria in chronic glomerular disease.
    Masunaga Y, Tabei K, Takeda S, Ando Y, Kusano E, Asano Y.
    Nihon Jinzo Gakkai Shi; 1993 Aug 02; 35(8):961-6. PubMed ID: 8255007
    [Abstract] [Full Text] [Related]

  • 33. Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease.
    Hemmelder MH, de Zeeuw D, de Jong PE.
    Nephrol Dial Transplant; 1999 Jan 02; 14(1):98-104. PubMed ID: 10052485
    [Abstract] [Full Text] [Related]

  • 34. Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease.
    Wapstra FH, Navis G, de Jong PE, de Zeeuw D.
    Exp Nephrol; 1996 Jan 02; 4 Suppl 1():47-52. PubMed ID: 9001897
    [Abstract] [Full Text] [Related]

  • 35. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
    Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS, AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease.
    Kidney Int; 2001 Sep 02; 60(3):1131-40. PubMed ID: 11532109
    [Abstract] [Full Text] [Related]

  • 36. Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.
    De Nicola L, Conte G, Russo D, Gorini A, Minutolo R.
    BMC Nephrol; 2012 Nov 20; 13():150. PubMed ID: 23167771
    [Abstract] [Full Text] [Related]

  • 37. Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis.
    Iodice C, Balletta MM, Minutolo R, Giannattasio P, Tuccillo S, Bellizzi V, D'Amora M, Rinaldi G, Signoriello G, Conte G, De Nicola L.
    Kidney Int; 2003 Jun 20; 63(6):2214-21. PubMed ID: 12753310
    [Abstract] [Full Text] [Related]

  • 38. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function.
    van Paassen P, de Zeeuw D, Navis G, de Jong PE.
    Nephrol Dial Transplant; 2000 May 20; 15(5):637-43. PubMed ID: 10809804
    [Abstract] [Full Text] [Related]

  • 39. Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system.
    Himmelmann A, Bergbrant A, Svensson A, Hansson L, Aurell M.
    Am J Hypertens; 1996 Jun 20; 9(6):517-22. PubMed ID: 8783774
    [Abstract] [Full Text] [Related]

  • 40. Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy.
    Haas M, Leko-Mohr Z, Erler C, Mayer G.
    Am J Kidney Dis; 2002 Sep 20; 40(3):458-63. PubMed ID: 12200795
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.